Geode Capital Management LLC increased its stake in UroGen Pharma Ltd. by 8.1% in Q3, now owning 455,637 shares valued at $5.79 million. Other institutional investors, including RTW Investments and Great Point Partners, also raised their holdings. UroGen Pharma’s stock rose 4.8% recently, trading at $11.21, with a market cap of $262.92 million. The company reported a net loss of $0.55 per share, exceeding analyst expectations. Analysts generally maintain a “buy” rating, with target prices ranging from $25 to $60. UroGen Pharma specializes in developing solutions for urothelial and specialty cancers.